FDA Clears Single-Use Antibacterial Surgical Respirator
The U.S. Food and Drug Administration cleared the SpectraShield 9500 N95 surgical respirator, a device that kills 99.99 percent of three different kinds of bacteria when exposed to its outer surface.
The FDA has cleared the SpectraShield as a single-use, N95 surgical respirator for use in healthcare settings by healthcare personnel to protect against microorganisms, body fluids and particulate material.
Data from laboratory tests demonstrated that the respirator is effective against the following bacteria: Streptococcus pyogenes, methicillin-resistant Staphylococcus aureus (MRSA) and Haemophilus influenzae.
"The SpectraShield 9500 N95 anti-bacterial surgical respirator may reduce the risk of exposure to specific bacterial agents during medical emergencies," says Elizabeth Claverie-Williams, branch chief of Infection Control Devices at the FDA's Center for Devices and Radiological Health.
N95 surgical respirators are different than regular facemasks, which are designed to help block large-particle droplets, splashes, sprays, or splatter that may contain viruses and bacteria from reaching the mouth and nose.
While a regular facemask may be effective in blocking splashes and large-particle droplets, it does not filter or block tiny particles that may be transmitted by coughs, sneezes, or certain medical procedures. Regular facemasks also do not provide complete protection from germs and other contaminants because of the loose fit between the surface and the face.
The N95 designation means that the respirator blocks at least 95 percent of very small particles when subjected to careful testing. If properly fitted, the capabilities of N95 respirators exceed those of regular facemasks. Even a properly fitted N95 respirator, however, does not eliminate the risk of infection, illness, or death.
N95 surgical respirators cleared by the FDA for use in healthcare settings, including the SpectraShield 9500 N95 surgical respirator, have also been evaluated by the National Institute for Occupational Safety and Health, part of the Centers for Disease Control and Prevention.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
